Why did Sarepta Therapeutics (SRPT) stock move recently?

On 9/8/2026, Sarepta Therapeutics moved -22.0% — Sarepta fell in sympathy after Novartis said its del-desiran candidate missed its Phase 3 endpoint in myotonic dystrophy. Investors read the failure across to other developers of muscle-disease therapies. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Sarepta Therapeutics (SRPT) overvalued or fairly valued?

MarketChacha shows Sarepta Therapeutics's valuation in context — a forward P/E of about 7.4, a price-to-book of about 1.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Sarepta Therapeutics's revenue?

Sarepta Therapeutics reported revenue of $1.9B for FY2025, with net profit of $-713.4M, per official filings.

What is the share price of Sarepta Therapeutics (SRPT)?

Sarepta Therapeutics last traded at $19.17 (+8.1% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Sarepta Therapeutics

SRPT · NYSE · Healthcare · United States

Snapshot

TickerSRPT

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees835

HeadquartersCambridge, United States

Websitewww.sarepta.com

Filings tracked19

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Who owns it

Insiders4.9%
Institutions95.1%
Public & other0.0%

440 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.17.98%
State Street Corporation8.44%
Vanguard Portfolio Management LLC7.93%
Vanguard Capital Management LLC4.35%
Two Sigma Investments, LP4.35%
First Trust Advisors LP4.13%
AQR Capital Management, LLC4.10%
Geode Capital Management, LLC2.62%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -62.5% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-46.8% → -38.3%

Margin has expanded by about 8.5 points — the business is getting more profitable.

Return on equity-62.5%

Latest ROE of -62.5% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $350.3M · EPS 0.12

Est. earnings growth +103.3%

Next fiscal year

Rev $1.4B · EPS 2.45

Est. earnings growth -43.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.9B

Net margin

-38.3%

ROE

-62.5%

Revenue CAGR (2y)

+27.6%

EPS (FY2025)

-7.13

Net profit (FY2025)

$-713.4M

Ask MarketChacha about SRPT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 8, 2026
Sarepta fell in sympathy after Novartis said its del-desiran candidate missed its Phase 3 endpoint in myotonic dystrophy. Investors read the failure across to other developers of muscle-disease therapies.
source 1 ↗source 2 ↗· confidence: high
Aug 25, 2026
SRPT rose on news that the company is resuming US shipments of its Elevidys gene therapy for ambulatory Duchenne patients after receiving FDA clearance to do so, following an earlier safety-related pause.
source 1 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about SRPT

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.9B	$-713.4M	-7.13	-38.3%	-62.5%
FY2024	$1.8B	$235.2M	2.34	13.2%	15.4%
FY2023	$1.1B	$-536.0M	-5.80	-46.8%	-62.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$328.7M	$-4.9M	-0.05	-1.5%
2026Q1	$330.5M	$331.0M*	2.88	—
2025Q4	$442.9M	$-412.2M	-3.93	-93.1%
2025Q3	$370.0M	$-50.6M	-0.50	-13.7%
2025Q2	$513.1M	$196.9M	1.89	38.4%
2025Q1	$611.5M	$-447.5M	-4.60	-73.2%
2024Q4	$658.4M	$159.0M	1.50	24.2%
2024Q3	$429.8M	$33.6M	0.34	7.8%
2024Q2	$360.5M	$6.5M	0.07	1.8%
2024Q1	$359.5M	$36.1M	0.37	10.0%
2023Q3	$309.3M	$-40.9M	-0.46	-13.2%
2023Q2	$239.0M	$-23.9M	-0.27	-10.0%
2023Q1	$231.5M	$-516.8M	-5.86	-223.2%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC8/5/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC7/27/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/4/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/6/2026material
10-K filing
SEC3/2/2026
8-K — Results of operations, Exhibits
SEC2/25/2026material
8-K — Executive/director change
SEC2/25/2026material
8-K — Results of operations, Exhibits
SEC1/12/2026material

2025

8-K — Material agreement, Material financial obligation, Exhibits
SEC12/19/2025material
8-K — Unregistered equity sale, Other events, Exhibits
SEC12/11/2025material
8-K — Executive/director change, Exhibits
SEC12/8/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC11/3/2025material
8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC8/29/2025material
8-K — Unregistered equity sale
SEC8/21/2025material
8-K — Executive/director change
SEC8/13/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.